RxDoctor Payments Data

Igor Kirzhner, MD

Psychiatry · Amityville, NYNPI 1942311915

Payments from drug & device makers

$2,540in general payments, 2019–2025

Across 83 payments — averaging $30.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$703
  • Lundbeck LLC$508
  • Axsome Therapeutics, Inc.$333
  • E.r. Squibb & Sons, L.L.C.$148
  • Alkermes, Inc.$140
  • Vanda Pharmaceuticals Inc.$116
  • plus $593 from 9 others

What the payments were for

  • Food & beverage$2,49598%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,540 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$472,755
Medicare patients
560
Services billed
4,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole133$235,508
Invega SustennaPaliperidone Palmitate54$137,527
Abilify MaintenaAripiprazole48$106,570
Tetrabenazine23$53,082
TrintellixVortioxetine Hydrobromide96$51,222
Invega TrinzaPaliperidone Palmitate11$49,451
AtivanLorazepam11$31,063
BelsomraSuvorexant74$30,437
VraylarCariprazine Hcl13$21,840
NamzaricMemantine Hcl/Donepezil Hcl28$21,166
Doxepin Hcl99$17,719
Lurasidone Hcl32$8,415
DayvigoLemborexant23$7,551
SilenorDoxepin Hcl12$6,359
NeurontinGabapentin11$4,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$703$342,078181 claims
Johnson & JohnsonInvega Sustenna, Invega Trinza$93$186,97965 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$51,22296 claims
AbbVieVraylar, Namzaric$107$43,00641 claims
MerckBelsomra$19$30,43774 claims
Eisai Inc.Dayvigo$45$7,55123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Amityville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →